AR040337A1 - USE OF A COMBINATION OF A TYPE 5 (PDE5) PHOSPHODIESTERASE INHIBITOR SPECIFY OF CYCLIC GUANOSINE MONOPHOSPHATE (GMPC) AND AN ANGIOTENSIN II RECEIVER ANTAGONIST TO PREPARE A MEDICINAL PRODUCT - Google Patents
USE OF A COMBINATION OF A TYPE 5 (PDE5) PHOSPHODIESTERASE INHIBITOR SPECIFY OF CYCLIC GUANOSINE MONOPHOSPHATE (GMPC) AND AN ANGIOTENSIN II RECEIVER ANTAGONIST TO PREPARE A MEDICINAL PRODUCTInfo
- Publication number
- AR040337A1 AR040337A1 ARP030102252A ARP030102252A AR040337A1 AR 040337 A1 AR040337 A1 AR 040337A1 AR P030102252 A ARP030102252 A AR P030102252A AR P030102252 A ARP030102252 A AR P030102252A AR 040337 A1 AR040337 A1 AR 040337A1
- Authority
- AR
- Argentina
- Prior art keywords
- sildenafil citrate
- methyl
- hypertension
- pyrazolo
- pyrimidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: El uso de una combinación de un inhibidor de fosfodiesterasa tipo 5 (PDE5) específica de monofosfato de guanosina (GMPc) y un antagonista del receptor de angiotensina II para preparar un medicamento caracterizado porque es para tratamiento paliativo, curativo o profiláctico de hipertensión, incluyendo hipertensión esencial, hipertensión pulmonar, hipertensión secundaria, hipertensión sistólica aislada, hipertensión asociada con diabetes, hipertensión asociada con aterosclerosis e hipretensión renovascuolar, insuficiencia cardiaca congestiva, angina, ictus, diabetes y trastornos de tolerancia a la glucosa. Reivindicación 4: El uso según cualquiera de la reivindicaciones anteriores, caracterizado porque el inhibidor de PDE5 se selecciona de 5-[2-etoxi-5-(4-metil-1-piperazinilsulfonil)fenil]-1-metil-3-n-propil-1,6-dihidro-7H-pirazolo[4,3-d]pirimidin-7-ona (sildenafilo); (6R,12aR)-2,3,6,7,12,12a-hexahidro-2-metil-6-(3,4-metilendioxifenil)-pirazino[2',1':6,1]pirido[3,4-b]indol-1,4-diona (tadalafilo); 2-[2-etoxi-5-(4-etil-piperazin-1-il-1-sulfonil)-fenil]-5-metil-7-propil-3H-imidazo[5,1-f][1,2,4]triazin-4-ona (vardenafilo); 3-(1-metil-7-oxo-3-propil-6,7-dihidro-1H-pirazolo[4,3-d]pirimidin-5-il)-N-(2-(1-metilpirrolidin-2-il)etil)-4-propoxibencenosulfonamida; 5-[2-etoxi-5-(4-etilpiperazin-1-ilsulfonil)piridin-3-il]-3-etil-2-[2-metoxietil]-2,6-dihidro-7H-pirazolo[4,3-d]pirimidin-7-ona; y 5-(5-acetil-2-butoxi-3-piridinil)-3-etil-2-)1-etil-3-azetidinil)-2,6-dihidro-7H-pirazolo[4,3-d]pirimidin-7-ona y las sales farmacéuticamente aceptables de los mismos. Reivindicación 5: El uso según la reivindicación 4, caracterizado porque el inhibidor de PDE5 se selecciona de 5-[2-etoxi-5-(4-metil-1-piperazinilsulfonil)fenil]-1-metil-3-n-propil-1,6-dihidro-7H-pirazolo[4,3-d]pirimidin-7-ona (sildenafilo) y las sales farmacéuticamente aceptables del mismo. Reivindicación 6: El uso según la reivindicación 5, caracterizado porque el inhibidor de PDE5 es citrato de sildenafilo. Reivindicación 7: El uso según cualquiera de las reivindicaciones anteriores, caracterizado porque el antagonista del receptor de angiotensina II se selecciona entre candesartano, eprosartano, irbesartano, losartano, olmesartano, medoxomil olmesartano, saralasino, telmisartano y valsartano y sales farmacéuticamente aceptables de los mismos. Reivindicación 8: El uso según la reivindicación 7, caracterizado porque la combinación del inhibidor de PDE5 y el antagonista del receptor de angiotensina II se selecciona entre citrato de sildenafilo y candesartano; citrato de sildenafilo y eprosartano citrato de sildenafilo e irbesartano; citrato de sildenafilo y losartano; citrato de sildenafilo y olmesartano; citrato de sildenafilo y medoxomil olmesartano; citrato de sildenafilo y telmisartano; y citrato de sildenafilo y valsartan.Claim 1: The use of a combination of a guanosine monophosphate specific type 5 (PDE5) phosphodiesterase inhibitor (cGMP) and an angiotensin II receptor antagonist to prepare a medicament characterized in that it is for palliative, curative or prophylactic hypertension treatment. , including essential hypertension, pulmonary hypertension, secondary hypertension, isolated systolic hypertension, hypertension associated with diabetes, hypertension associated with atherosclerosis and renovascuolar hypretension, congestive heart failure, angina, stroke, diabetes and glucose tolerance disorders. Claim 4: The use according to any of the preceding claims, characterized in that the PDE5 inhibitor is selected from 5- [2-ethoxy-5- (4-methyl-1-piperazinylsulfonyl) phenyl] -1-methyl-3-n- propyl-1,6-dihydro-7H-pyrazolo [4,3-d] pyrimidin-7-one (sildenafil); (6R, 12aR) -2,3,6,7,12,12a-hexahydro-2-methyl-6- (3,4-methylenedioxyphenyl) -pyrazino [2 ', 1': 6.1] pyrido [3, 4-b] indole-1,4-dione (tadalafil); 2- [2-Ethoxy-5- (4-ethyl-piperazin-1-yl-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5,1-f] [1,2 , 4] triazin-4-one (vardenafil); 3- (1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d] pyrimidin-5-yl) -N- (2- (1-methylpyrrolidin-2- il) ethyl) -4-propoxybenzenesulfonamide; 5- [2-Ethoxy-5- (4-ethylpiperazin-1-ylsulfonyl) pyridin-3-yl] -3-ethyl-2- [2-methoxyethyl] -2,6-dihydro-7H-pyrazolo [4,3 -d] pyrimidin-7-one; and 5- (5-acetyl-2-butoxy-3-pyridinyl) -3-ethyl-2-) 1-ethyl-3-azetidinyl) -2,6-dihydro-7H-pyrazolo [4,3-d] pyrimidin -7-one and the pharmaceutically acceptable salts thereof. Claim 5: The use according to claim 4, characterized in that the PDE5 inhibitor is selected from 5- [2-ethoxy-5- (4-methyl-1-piperazinylsulfonyl) phenyl] -1-methyl-3-n-propyl- 1,6-dihydro-7H-pyrazolo [4,3-d] pyrimidin-7-one (sildenafil) and pharmaceutically acceptable salts thereof. Claim 6: The use according to claim 5, characterized in that the PDE5 inhibitor is sildenafil citrate. Claim 7: The use according to any of the preceding claims, characterized in that the angiotensin II receptor antagonist is selected from candesartan, eprosartan, irbesartan, losartan, olmesartan, medoxomil olmesartan, Saralasin, telmisartan and valsartan and pharmaceutically acceptable salts thereof. Claim 8: The use according to claim 7, characterized in that the combination of the PDE5 inhibitor and the angiotensin II receptor antagonist is selected from sildenafil citrate and candesartan; sildenafil citrate and eprosartan sildenafil citrate and irbesartan; sildenafil citrate and losartan; sildenafil citrate and olmesartan; Sildenafil Citrate and Medoxomil Olmesartan; sildenafil citrate and telmisartan; and sildenafil citrate and valsartan.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0214784.1A GB0214784D0 (en) | 2002-06-26 | 2002-06-26 | Novel combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040337A1 true AR040337A1 (en) | 2005-03-30 |
Family
ID=9939342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102252A AR040337A1 (en) | 2002-06-26 | 2003-06-24 | USE OF A COMBINATION OF A TYPE 5 (PDE5) PHOSPHODIESTERASE INHIBITOR SPECIFY OF CYCLIC GUANOSINE MONOPHOSPHATE (GMPC) AND AN ANGIOTENSIN II RECEIVER ANTAGONIST TO PREPARE A MEDICINAL PRODUCT |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1524996A2 (en) |
| JP (1) | JP2005531627A (en) |
| KR (1) | KR20050013156A (en) |
| CN (1) | CN1662257A (en) |
| AR (1) | AR040337A1 (en) |
| AU (1) | AU2003242895A1 (en) |
| BR (1) | BR0312030A (en) |
| CA (1) | CA2491002A1 (en) |
| GB (1) | GB0214784D0 (en) |
| GT (1) | GT200300124A (en) |
| MX (1) | MXPA04012569A (en) |
| NO (1) | NO20050400L (en) |
| PA (1) | PA8575501A1 (en) |
| PE (1) | PE20040868A1 (en) |
| PL (1) | PL375079A1 (en) |
| RU (1) | RU2004136276A (en) |
| TW (1) | TW200404546A (en) |
| UY (1) | UY27863A1 (en) |
| WO (1) | WO2004002461A2 (en) |
| ZA (1) | ZA200409532B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| US7756327B2 (en) * | 2002-07-26 | 2010-07-13 | Olympus Corporation | Image processing system having multiple imaging modes |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| BRPI0502411A (en) * | 2005-03-31 | 2006-11-28 | Univ Minas Gerais | process of developing substances as potent and selective inhibitors of phosphodiesterase isoforms of types 1 to 5 (pde1, pde2, pde3, pde4, pde5) based on diocleine, fluranol or analogs and their pharmaceutical compositions for the study and treatment of cardiovascular disease and associated products |
| JP4879977B2 (en) * | 2005-06-10 | 2012-02-22 | ドン・ア・ファーム・カンパニー・リミテッド | Preventive and therapeutic agents for liver diseases containing pyrazolopyrimidinone derivatives |
| EP1909793A2 (en) * | 2005-07-15 | 2008-04-16 | Proxomed Medizintechnik GmbH | Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors |
| AU2006304787A1 (en) * | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| US7858611B2 (en) | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| EP2021000A2 (en) * | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| PL194801B1 (en) * | 1997-11-12 | 2007-07-31 | Bayer Healthcare Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| SK4562002A3 (en) * | 1999-10-11 | 2003-04-01 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
| TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| KR20030023747A (en) * | 2000-08-11 | 2003-03-19 | 화이자 인코포레이티드 | Treatment of the insulin resistance syndrome |
-
2002
- 2002-06-26 GB GBGB0214784.1A patent/GB0214784D0/en not_active Ceased
-
2003
- 2003-06-04 GT GT200300124A patent/GT200300124A/en unknown
- 2003-06-13 PA PA20038575501A patent/PA8575501A1/en unknown
- 2003-06-16 CA CA002491002A patent/CA2491002A1/en not_active Abandoned
- 2003-06-16 KR KR10-2004-7021041A patent/KR20050013156A/en not_active Application Discontinuation
- 2003-06-16 CN CN03814574XA patent/CN1662257A/en active Pending
- 2003-06-16 JP JP2004517093A patent/JP2005531627A/en not_active Withdrawn
- 2003-06-16 EP EP03761725A patent/EP1524996A2/en not_active Withdrawn
- 2003-06-16 AU AU2003242895A patent/AU2003242895A1/en not_active Abandoned
- 2003-06-16 BR BR0312030-9A patent/BR0312030A/en not_active IP Right Cessation
- 2003-06-16 RU RU2004136276/15A patent/RU2004136276A/en not_active Application Discontinuation
- 2003-06-16 PL PL03375079A patent/PL375079A1/en not_active Application Discontinuation
- 2003-06-16 WO PCT/IB2003/002657 patent/WO2004002461A2/en not_active Application Discontinuation
- 2003-06-16 MX MXPA04012569A patent/MXPA04012569A/en unknown
- 2003-06-20 TW TW092116851A patent/TW200404546A/en unknown
- 2003-06-24 PE PE2003000636A patent/PE20040868A1/en not_active Application Discontinuation
- 2003-06-24 UY UY27863A patent/UY27863A1/en not_active Application Discontinuation
- 2003-06-24 AR ARP030102252A patent/AR040337A1/en not_active Application Discontinuation
-
2004
- 2004-11-25 ZA ZA200409532A patent/ZA200409532B/en unknown
-
2005
- 2005-01-25 NO NO20050400A patent/NO20050400L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200404546A (en) | 2004-04-01 |
| AU2003242895A1 (en) | 2004-01-19 |
| GT200300124A (en) | 2004-03-17 |
| MXPA04012569A (en) | 2005-04-19 |
| CN1662257A (en) | 2005-08-31 |
| EP1524996A2 (en) | 2005-04-27 |
| WO2004002461A3 (en) | 2004-05-13 |
| BR0312030A (en) | 2005-03-22 |
| PE20040868A1 (en) | 2004-11-25 |
| JP2005531627A (en) | 2005-10-20 |
| PL375079A1 (en) | 2005-11-14 |
| RU2004136276A (en) | 2005-09-10 |
| CA2491002A1 (en) | 2004-01-08 |
| KR20050013156A (en) | 2005-02-02 |
| WO2004002461A2 (en) | 2004-01-08 |
| PA8575501A1 (en) | 2003-12-30 |
| NO20050400L (en) | 2005-03-29 |
| GB0214784D0 (en) | 2002-08-07 |
| UY27863A1 (en) | 2003-12-31 |
| ZA200409532B (en) | 2006-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150987T1 (en) | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | |
| KR100997601B1 (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity | |
| JP2013526598A5 (en) | ||
| RS52730B (en) | Composition comprising a pde4 inhibitor and a pde5 inhibitor | |
| CA2607021C (en) | Diaryl-purines, -azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv | |
| EP3079700B1 (en) | Soluble guanylate cyclase activators | |
| RU2008131792A (en) | COMBINATION OF NORADRENALINE AND NORADRENALINE SELF-REVERSE INHIBITOR AND PDEV INHIBITOR | |
| TW200831103A (en) | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | |
| AR040337A1 (en) | USE OF A COMBINATION OF A TYPE 5 (PDE5) PHOSPHODIESTERASE INHIBITOR SPECIFY OF CYCLIC GUANOSINE MONOPHOSPHATE (GMPC) AND AN ANGIOTENSIN II RECEIVER ANTAGONIST TO PREPARE A MEDICINAL PRODUCT | |
| ATE298238T1 (en) | PYRAZOLO(4,3-D)PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS | |
| AU2015349888A1 (en) | Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators | |
| RS53245B (en) | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile | |
| PE20130779A1 (en) | PYRIMIDINES AND CONDENSED TRIAZINES AND THEIR USE | |
| JP2018507861A5 (en) | ||
| PE20051061A1 (en) | 5,7-DIAMINOPYRAZOLE [4,3-d] PYRIMIDINES | |
| US20160304536A1 (en) | Soluble guanylate cyclase activators | |
| US11166956B2 (en) | Combinations of PDE1 inhibitors and NEP inhibitors | |
| HRP20131210T1 (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors | |
| WO2004096811A1 (en) | Pde9 inhibitors for treating type 2 diabetes, metabokic syndrome, and cardiovascular disease | |
| EA200601496A1 (en) | 8- [3-AMINOPIPERIDIN-1-IL] XANTHINES, THEIR RECEIVING AND THEIR USE AS DPP-IV Inhibitors | |
| PE20120121A1 (en) | IMIDAZOPYRAZINE DERIVATIVES AS SYK INHIBITORS | |
| AR062501A1 (en) | THERAPEUTIC COMPOSITIONS | |
| CA2687766A1 (en) | Azaindazole compounds and methods of use | |
| MX2021003241A (en) | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto. | |
| GB0613693D0 (en) | Benzodiazepine salts (3) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |